Rotavirus Prophylaxis Market Size, Scope Analysis, Key Insights, Leading Key Players, And Forecast To 2033

The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.

Rotavirus Prophylaxis Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.

The Market Size Is Expected To Reach $13.24 billion In 2028 At A CAGR Of 10.0% :

The rotavirus prophylaxis market size has grown rapidly in recent years. It will grow from $8.15 billion in 2023 to $9.05 billion in 2024 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to vaccine access and equity, emerging rotavirus strains, r&d investments, public health preparedness.

The rotavirus prophylaxis market size is expected to see strong growth in the next few years. It will grow to $13.24 billion in 2028 at a compound annual growth rate (CAGR) of 10.0%. The growth in the forecast period can be attributed to gastrointestinal disease burden, global expansion, vaccination programs, vaccine confidence. Major trends in the forecast period include next-generation vaccines, combination vaccines, vaccine delivery innovation, global immunization collaboration.

Request A Sample Of This Report - https://www.thebusinessresearchcompany.com/sample.aspx?id=13045&type=smp

Rotavirus Prophylaxis Market Major Segments
The rotavirus prophylaxis market covered in this report is segmented -

1) By Treatment: Rotarix; Rotavac; Rotavin-M1; Oral Rehydration Fluid; Other Treatments
2) By Route of Administration: Oral; Parenteral; Other Route of Administrations
3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
4) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users

Key Driver - Rising Vaccine Courses Powering Growth In The Rotavirus Prophylaxis Market

The increasing vaccine courses are expected to propel the growth of the rotavirus prophylaxis market going forward. A vaccine course is a specific dose of vaccine that is meant to be given to a person to produce protection from a particular disease. The vaccine course dosage stimulates the immunological response, providing excellent protection against rotavirus infection. This increased immunity minimizes the risk of diseases and improves the vaccine's overall efficacy. For instance, in January 2022, according to a report published by the United Nations International Children's Emergency Fund (UNICEF), a US-based provider of humanitarian and developmental help to children, around 5.71 million courses of RV1-5 frozen rotavirus vaccine were produced 2022, with a projected increase to 9.31 million courses by 2028. Furthermore, 5.29 million courses of RV5-2 lyophilized rotavirus vaccines were manufactured in 2022, with a projected rise to 6.13 million courses by 2028. Therefore, the increasing number of vaccines will drive the rotavirus prophylaxis market.

Customise This Report As Per Your Requirements - https://www.thebusinessresearchcompany.com/Customise?id=13045&type=smp

Prominent Trend - Vaccine Development And Approvals In The Rotavirus Prophylaxis Market

Major companies operating in the rotavirus prophylaxis market are developing vaccines to meet customer requirements. Vaccine approvals involve a rigorous process that includes multiple development and testing stages. These approvals are essential in ensuring that vaccines are safe and effective for preventing this viral illness, particularly in infants and young children. For instance, in November 2022, GlaxoSmithKline plc, a UK-based pharmaceutical and biotechnology company, announced that the Food and Drug Administration (FDA) had approved an oral-dosing applicator-only presentation (liquid formulation) of ROTARIX (Rotavirus Vaccine, Live and Oral), that prevents rotavirus gastroenteritis caused by G1 and non-G1 types (G3, G4 and G9) in infants. The novel oral-dosing applicator-only presentation is entirely liquid and must not be reconstituted before use. ROTARIX lyophilized and liquid formulations are administered orally in a two-dose series, contain the same live, human-attenuated rotavirus strain and are made using comparable techniques.

Rotavirus Prophylaxis Market Players
Major players in the rotavirus prophylaxis market are Pfizer Inc., Johnson & Johnson, Merck & Co., Novartis AG, Sanofi SA, Astra Zeneca Pharmaceuticals LP, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Sinovac Biotech Ltd., Astellas Pharma Inc., CSL Limited, Bharat Biotech International Limited, Daiichi Sankyo Co. Ltd., Lupin Limited, Mitsubishi Tanabe Pharma Corporation, Serum Institute of India Pvt. Ltd., Zydus Lifescience Ltd., Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Biocad Biopharmaceutical Co., Bharat Serums and Vaccines Limited, Biological E Limited, PT Bio Farma, Panacea Biotec Ltd., Shanghai Institute of Biological Products (SIBP).

View The Full Report Here - https://www.thebusinessresearchcompany.com/report/rotavirus-prophylaxis-global-market-report

Largest And Fastest Growing Region In The Market
North America was the largest region in the rotavirus prophylaxis market in 2023. The regions covered in rotavirus prophylaxis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Rotavirus Prophylaxis Market Report Structure
3. Rotavirus Prophylaxis Market Trends And Strategies
4. Rotavirus Prophylaxis Market - Macro Economic Scenario
5. Rotavirus Prophylaxis Market Size And Growth
…..
27. Rotavirus Prophylaxis Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.